• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Daratumumab for the treatment of multiple myeloma
【24h】

Daratumumab for the treatment of multiple myeloma

机译：达拉姆巴布治疗多发性骨髓瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Proteasome inhibitors and immunomodulatory drugs have contributed to the dramatic improvement in survival for patients with myeloma over the past decades. However, the disease typically relapses and new classes of drugs are needed. In 2015, two monoclonal antibodies were approved for the treatment of patients with relapsed multiple myeloma, and immunotherapy has rapidly become indispensable in the management of myeloma patients.Areas covered: Here, the authors discuss the published data regarding the mechanism of action, safety and clinical efficacy of the CD38-targeted monoclonal antibody daratumumab for the treatment of patients with multiple myeloma.Expert opinion: Daratumumab is indicated for myeloma patients who have received at least 3 prior therapies, including bortezomib, lenalidomide and pomalidomide. In 2016, daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone was approved for the treatment of patients with multiple myeloma who have received at least one prior therapy. Daratumumab displays an excellent safety profile. Moderate-grade infusion-related reactions occurring mostly during the first infusion are the main treatment-emergent adverse event. In the context of daratumumab therapy, attention should be paid to interference with blood compatibility testing and response assessment. Daratumumab-based combination therapies are currently under evaluation in relapsed and newly diagnosed patients.
机译：介绍：蛋白酶体抑制剂和免疫调节药物对过去几十年来患骨髓瘤患者的存活率急剧提高。然而，该疾病通常需要复发，需要新的药物。 2015年，批准了两种单克隆抗体用于治疗复发多发性骨髓瘤的患者，并且免疫疗法在骨髓瘤患者的管理中迅速变得不可或缺。涉及：在这里，作者讨论了关于行动机制，安全和安全机制的公布数据CD38靶向单克隆抗体达拉汀患者治疗多发性骨髓瘤患者的临床疗效。患有意见：Daratumumab用于接受至少3个以前疗法的骨髓瘤患者，包括Bortezomib，Lenalidomide和Pomalidomide。 2016年，Daratumumab与Lenalalomide和DexameThasone组合，或硼替佐米和地塞米松被批准用于治疗有患有至少一个先前治疗的多发性骨髓瘤的患者。 Daratumumab显示出优秀的安全型材。在第一次输注期间，主要发生的中等级输液相关的反应是主要的治疗紧急不良事件。在达拉姆巴布治疗的背景下，应注意干扰血液兼容性测试和响应评估。基于Daratumumab的组合疗法目前正在评估复发和新诊断的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号